Drug Approval | January 28, 2023
USFDA provides exception to Glenmark's Baddi facility
The company will engage with the agency to resolve the import alert at the earliest.
The company will engage with the agency to resolve the import alert at the earliest.
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Subscribe To Our Newsletter & Stay Updated
